Myeloma Nurse Learning Programme Module 7 – Drug development and new treatments in myeloma Key points

Key points

  • The process of drug development is highly complex, time consuming and costly with no guarantee that a drug will be brought to market
  • The process of bringing a drug to market is tightly regulated and requires a series of clinical trials to prove efficacy and safety in the target patient population. Each phase addresses specific questions which must be answered before proceeding to the next phase
  • A greater understanding of the biology of myeloma is leading to the development of next generation treatments of those that have shown success in myeloma and novel drugs that target specific cellular processes.
  • In the future, more personalised treatment options and better risk stratification of patients will hopefully allow more tolerated and effective treatment regimens that improve both overall survival and quality of life
  • For the most up-to-date clinical trials and drugs available in the UK for myeloma please visit our Myeloma Trial Finder and Myeloma Drug Tracker sites.
Previous Section
Back to Module
Next Assessment